These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 14960504

  • 21. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [Abstract] [Full Text] [Related]

  • 22. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL, Januszewicz A.
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [Abstract] [Full Text] [Related]

  • 23. Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)--rationale and protocol for the main trial.
    Marre M, Garcia Puig J, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, Halabe A, Williams B, Mion D, Ruiz M, Hermansen K, Tuomilehto J, Finizola B, Pozza G, Chastang C, Ollivier JP, Amouyel P, Asmar R.
    J Hypertens Suppl; 2003 Mar; 21(1):S19-24. PubMed ID: 12769163
    [Abstract] [Full Text] [Related]

  • 24. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group.
    Trevisan R, Tiengo A.
    Am J Hypertens; 1995 Sep; 8(9):876-83. PubMed ID: 8541002
    [Abstract] [Full Text] [Related]

  • 25. Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.
    Borcea V, Morcos M, Isermann B, Henkels M, Ziegler S, Zumbach M, Amiral J, Längst KD, Seiz W, Ziegler R, Wahl P, Nawroth PP.
    Vasa; 1999 Aug; 28(3):172-80. PubMed ID: 10483322
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
    Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S, ONTARGET Investigators.
    J Am Coll Cardiol; 2012 Jan 03; 59(1):74-83. PubMed ID: 22192672
    [Abstract] [Full Text] [Related]

  • 29. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.
    Lancet; 1997 Jun 21; 349(9068):1787-92. PubMed ID: 9269212
    [Abstract] [Full Text] [Related]

  • 30. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.
    Lièvre M, Marre M, Chatellier G, Plouin P, Réglier J, Richardson L, Bugnard F, Vasmant D.
    Control Clin Trials; 2000 Aug 21; 21(4):383-96. PubMed ID: 10913814
    [Abstract] [Full Text] [Related]

  • 31. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators.
    Lancet; 2008 Aug 16; 372(9638):547-53. PubMed ID: 18707986
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.
    Vaur L, Gueret P, Lievre M, Chabaud S, Passa P, DIABHYCAR Study Group (type 2 DIABetes, Hypertension, CARdiovascular Events and Ramipril) study.
    Diabetes Care; 2003 Mar 16; 26(3):855-60. PubMed ID: 12610049
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
    Warner GT, Perry CM.
    Drugs; 2002 Mar 16; 62(9):1381-405. PubMed ID: 12076194
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.
    Gerstein HC, Bosch J, Pogue J, Taylor DW, Zinman B, Yusuf S.
    Diabetes Care; 1996 Nov 16; 19(11):1225-8. PubMed ID: 8908384
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.